# Biotech Daily Digest — 2025-10-19

**5 items from 2 sources**

## Summary by Source

- Endpoints News: 2 items
- Fierce Biotech: 3 items


## Endpoints News

- **[Exclusive: Sid Mukherjee’s Faeth nets $25M for endometrial cancer study](https://endpoints.news/exclusive-sid-mukherjees-faeth-nets-25m-for-endometrial-cancer-study/)**  
  _Sun, 19 Oct 2025 09:01:24 +0000_  
  Faeth Therapeutics has collected another $25 million to fund tests of its thesis that metabolism and nutrition are key influences on cancer.

 The startup plans to put the money primarily towards a Phase 2 trial ...

- **[#ESMO25: Datroway, Trodelvy contest in triple negative breast cancer heats up](https://endpoints.news/esmo25-datroway-trodelvy-contest-in-triple-negative-breast-cancer-heats-up/)**  
  _Sun, 19 Oct 2025 08:14:23 +0000_  
  BERLIN – Results have been revealed for the much-anticipated showdown at this year’s ESMO congress between AstraZeneca and Daiichi Sankyo’s Datroway and Gilead’s Trodelvy. Although Datroway might have some edge, it seems that the two ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-tubulis-next-gen-adc-posts-59-response-rate-justifying-investor-interest" hreflang="en">ESMO: Tubulis’ next-gen ADC posts 59% response rate, justifying investor interest</a>](https://www.fiercebiotech.com/biotech/esmo-tubulis-next-gen-adc-posts-59-response-rate-justifying-investor-interest)**  
  _Oct 18, 2025 8:33am_  
  Tubulis’ next-generation ADC has been tied to an overall response rate of 59% as the German biotech tastes its first clinical success.

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-astrazeneca-believes-latest-data-validate-betting-house-adc-pipeline" hreflang="en">ESMO: AstraZeneca believes latest data 'validate' going it alone on next-gen ADCs</a>](https://www.fiercebiotech.com/biotech/esmo-astrazeneca-believes-latest-data-validate-betting-house-adc-pipeline)**  
  _Oct 18, 2025 10:57am_  
  Europe’s leading cancer conference may be swimming in ADC data, but AstraZeneca remains convinced its in-house pipeline sets the pharma apart.

- **[<a href="https://www.fiercebiotech.com/biotech/esmo-roche-wants-oral-serd-benefit-all-comers-unveils-phase-3-breast-cancer-data" hreflang="en">ESMO: Roche wants oral SERD to benefit 'all comers,' unveils phase 3 breast cancer data</a>](https://www.fiercebiotech.com/biotech/esmo-roche-wants-oral-serd-benefit-all-comers-unveils-phase-3-breast-cancer-data)**  
  _Oct 17, 2025 10:39am_  
  Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% in a specific cohort of a phase 3 trial.
